March 24, 2023

A Phase 1 Open-Label Study Of The Safety, Tolerability And Preliminary Clinical Activity Of Allogeneic Invariant Natural Killer (INKT) Non-Transduced Cells (AGENT-797) As A Single Agent And In Combination With Approved Immune Checkpoint Inhibitors In Patients With Relapsed/Refractory Solid Tumors